569 related articles for article (PubMed ID: 1289186)
1. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.
Locatelli F; Zecca M; Pedrazzoli P; Prete L; Quaglini S; Comoli P; De Stefano P; Beguin Y; Robustelli della Cuna G; Severi F
Bone Marrow Transplant; 1994 Apr; 13(4):403-10. PubMed ID: 8019464
[TBL] [Abstract][Full Text] [Related]
3. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function.
Nampoory MR; Johny KV; al-Hilali N; Seshadri MS; Kanagasabhapathy AS
Nephrol Dial Transplant; 1996 Jan; 11(1):177-81. PubMed ID: 8649630
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
Nowrousian MR
Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
[TBL] [Abstract][Full Text] [Related]
7. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
[TBL] [Abstract][Full Text] [Related]
8. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
Henry DH; Abels RI
Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
11. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B
Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327
[TBL] [Abstract][Full Text] [Related]
12. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
13. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure.
Opasich C; Cazzola M; Scelsi L; De Feo S; Bosimini E; Lagioia R; Febo O; Ferrari R; Fucili A; Moratti R; Tramarin R; Tavazzi L
Eur Heart J; 2005 Nov; 26(21):2232-7. PubMed ID: 15987710
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
15. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
16. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
17. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
18. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure.
Tomson CR; Edmunds ME; Chambers K; Bricknell S; Feehally J; Walls J
Nephrol Dial Transplant; 1992; 7(8):817-21. PubMed ID: 1325614
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics.
Cotes PM; Pippard MJ; Reid CD; Winearls CG; Oliver DO; Royston JP
Q J Med; 1989 Feb; 70(262):113-37. PubMed ID: 2594953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
